Dr. Gabrielle McLemore

Title: 
Associate Professor of Biology
Office Location: 
Spencer Hall 104
Phone: 
(443) 885-3633
Email: 
Gabrielle.McLemore@morgan.edu
Education:

Ph.D. Pharmacology, The Pennsylvania State University College of Medicine, 1994
B.S. Biology, The College of New Jersey (formerly Trenton State College), 1983

Education:

Ph.D. Pharmacology, The Pennsylvania State University College of Medicine, 1994
B.S. Biology, The College of New Jersey (formerly Trenton State College), 1983

Research Interests:

Monosodium urate de-crystallization with gold nanoparticles and low-power microwave heat in the MSUC-induced arthritic gout rat model.

Current Research:

Dr. McLemore's new research project will focus on developing an alternative gout treatment using monosodium urate de-crystallization with gold nanoparticles (AuNP) and low-power microwave heat (l-p MWH) in gouty rats. First, we will establish a monosodium urate crystal (MSUC)-induced arthritic gout rat model via injecting MSUCs into ankle joint tissues, visualizing MSUCs via optical imaging, characterizing the size and number of MSUCs, and assessing hyperalgesia and inflammation. Next, we will optimize the power and exposure time for the safe use of l-p MWH and establish the optimal AuNP size to use to assess the efficacy of our gout treatment. We hypothesize that in the gouty rat our alternative gout treatment, consisting of l-p MWH-accelerated AuNP ("nano-bullets"), is a more efficacious treatment than standard colchicine therapy (SCT). Finally, we will determine the efficacy of our gout treatment versus SCT via visualizing MSUC via optical imaging, characterizing MSUC size and number, and assessing hyperalgesia and inflammation after both treatments.

Courses Taught:

  • BIOL 101, Introductory Biology I for Non-Science Majors
  • BIOL 102, Introductory Biology II for Non-Science Majors

Selected Publications:

  • Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure - The "first hit" to the endocannabinoid system. Neurotoxicol Teratol. 2016 Aug 24. pii:S0892-0362(16)30078-2. doi: 10.1016/j.ntt.2016.08.003. [Epub ahead of print] Review. PubMed PMID: 27567698.
  • McLemore GL, Lewis T, Jones CH, Gauda EB. Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Semin Fetal Neonatal Med. 2013 Feb;18(1):35-41. doi: 10.1016/j.siny.2012.09.002. Review. PubMed PMID: 23059064; PubMed Central PMCID: PMC4142759.
  • Chavez-Valdez R, Kovell L, Ahlawat R, McLemore GL, Wills-Karp M, Gauda EB. Opioids and clonidine modulate cytokine production and opioid receptor expression in neonatal immune cells. J Perinatol. 2013 May;33(5):374-82. doi:10.1038/jp.2012.124. PubMed PMID: 23047422; PubMed Central PMCID: PMC3640758.
  • Gauda EB, Cooper RZ, Donnelly DF, Mason A, McLemore GL. The effect of development on the pattern of A1 and A2a-adenosine receptor gene and protein expression in rat peripheral arterial chemoreceptors. Adv Exp Med Biol. 2006;580:121-9; discussion 351-9. PubMed PMID: 16683708.
  • Richardson KA, Yohay AL, Gauda EB, McLemore GL. Neonatal animal models of opiate withdrawal. ILAR J. 2006;47(1):39-48. Review. PubMed PMID: 16391430.